Selinexor in acute myeloid leukemia: therapeutic applications and current challenges

This article aims to review the current application status and research advancements of selinexor in the treatment of acute myeloid leukemia (AML). Selinexor, as the first oral selective inhibitor of nuclear export protein Exportin-1 (XPO1), inhibits the abnormal nuclear export of tumor suppressor p...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Ziyu Qie, Li Ma, Jie Tan, Xiaochun Peng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	selinexor acute myeloid leukemia XPO1 inhibitor treatment strategy drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1602911/full